Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Debiopharm Innovation Fund
BioCentury | Mar 10, 2023
Regulation
March 10 Quick Takes: FDA approves Pfizer’s nasal spray for migraine
Plus: $50M series B, new CMO for cross-border play Allorion and updates from Merck & Co., Intercept, Iktos and more
BioCentury | May 10, 2022
Product Development
May 9 Quick Takes: Madrigal adds co-primary endpoint to NASH study
Plus first EU-listed life sciences SPAC launches and updates from Janssen, Myovant and more
BioCentury | Mar 10, 2017
Finance
Debiopharm’s new focus
Debiopharm shifts emphasis of venture fund from Dx to big data, therapeutics
Items per page:
1 - 6 of 6